Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorMedical University of South Carolina

About this trial

Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.

Eligibility criteria

Qualifiers

Age ≥18 and <60 years

Diagnosis of systemic sclerosis

Presence of sclerodactyly

Ability to provide informed consent

Disqualifiers

Known hypersensitivity to hyaluronidase

Pregnancy or breastfeeding

Unstable systemic disease

Recent changes in systemic immunomodulatory therapy

Trial design

Treatments tested in this trial

  • Hyaluronidase (Hylenex)

Treatment groups

10 Participants
are divided into 1 treatment group